CA2239733A1 - Gene de predisposition au cancer du sein lie au chromosome 13 - Google Patents

Gene de predisposition au cancer du sein lie au chromosome 13

Info

Publication number
CA2239733A1
CA2239733A1 CA002239733A CA2239733A CA2239733A1 CA 2239733 A1 CA2239733 A1 CA 2239733A1 CA 002239733 A CA002239733 A CA 002239733A CA 2239733 A CA2239733 A CA 2239733A CA 2239733 A1 CA2239733 A1 CA 2239733A1
Authority
CA
Canada
Prior art keywords
breast cancer
relates
gene
human
brca2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002239733A
Other languages
English (en)
Other versions
CA2239733C (fr
Inventor
Sean V. Tavtigian
Alexander Kamb
Jacques Simard
Fergus Couch
Johanna M. Rommens
Barbara L. Weber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Endorecherche Inc
HSC Research and Development LP
Myriad Genetics Inc
University of Pennsylvania Penn
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27541925&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2239733(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/639,501 external-priority patent/US5837492A/en
Application filed by Individual filed Critical Individual
Publication of CA2239733A1 publication Critical patent/CA2239733A1/fr
Application granted granted Critical
Publication of CA2239733C publication Critical patent/CA2239733C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/828—Cancer

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CA002239733A 1995-12-18 1996-12-17 Gene de predisposition au cancer du sein lie au chromosome 13 Expired - Fee Related CA2239733C (fr)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US57377995A 1995-12-18 1995-12-18
US08/573,779 1995-12-18
US57535995A 1995-12-20 1995-12-20
US08/575,359 1995-12-20
US57655995A 1995-12-21 1995-12-21
US08/576,559 1995-12-21
US58539196A 1996-01-11 1996-01-11
US08/585,391 1996-01-11
US08/639,501 1996-04-29
US08/639,501 US5837492A (en) 1995-12-18 1996-04-29 Chromosome 13-linked breast cancer susceptibility gene
PCT/US1996/019598 WO1997022689A1 (fr) 1995-12-18 1996-12-17 Gene de predisposition au cancer du sein lie au chromosome 13

Publications (2)

Publication Number Publication Date
CA2239733A1 true CA2239733A1 (fr) 1997-06-26
CA2239733C CA2239733C (fr) 2001-04-03

Family

ID=27541925

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002239733A Expired - Fee Related CA2239733C (fr) 1995-12-18 1996-12-17 Gene de predisposition au cancer du sein lie au chromosome 13

Country Status (11)

Country Link
US (2) US6124104A (fr)
EP (1) EP0785216B2 (fr)
JP (1) JP3455228B2 (fr)
AT (1) ATE230759T1 (fr)
AU (1) AU1461597A (fr)
CA (1) CA2239733C (fr)
DE (1) DE69625678T3 (fr)
IL (1) IL124620A0 (fr)
NO (1) NO982785L (fr)
NZ (1) NZ326525A (fr)
WO (1) WO1997022689A1 (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030022184A1 (en) * 1996-02-12 2003-01-30 Oncormed. Inc. Coding sequences of the human BRCA1 gene
US6838256B2 (en) 1996-02-12 2005-01-04 Gene Logic Inc. Coding sequences of the human BRCA1 gene
CA2273051A1 (fr) * 1996-12-03 1998-06-11 Prasanna Athma Predisposition au cancer du sein liee a des mutations affectant le locus du gene d'ataxie telangiectasie
GB9708221D0 (en) * 1997-04-23 1997-06-11 Cancer Res Campaign Tech Substances and uses thereof
US20090269814A1 (en) * 1998-05-22 2009-10-29 Murphy Patricia D Method of Analyzing a BRCA2 Gene in a Human Subject
EP2275575A3 (fr) * 1997-08-15 2012-07-11 Gene Logic Inc. Codage d'haplotypes de séquence de gène brca2 humain
US6492109B1 (en) 1997-09-23 2002-12-10 Gene Logic, Inc. Susceptibility mutation 6495delGC of BRCA2
US6051379A (en) * 1997-09-23 2000-04-18 Oncormed, Inc. Cancer susceptibility mutations of BRCA2
US6686163B2 (en) 1998-05-06 2004-02-03 Gene Logic Inc. Coding sequence haplotype of the human BRCA1 gene
US20030180789A1 (en) * 1998-12-30 2003-09-25 Dale Roderic M.K. Arrays with modified oligonucleotide and polynucleotide compositions
US6087112A (en) * 1998-12-30 2000-07-11 Oligos Etc. Inc. Arrays with modified oligonucleotide and polynucleotide compositions
US7148016B1 (en) * 1999-01-14 2006-12-12 Ca*Tx Inc. Immunoassays to detect diseases or disease susceptibility traits
AUPQ421699A0 (en) * 1999-11-24 1999-12-16 University Of Western Australia, The Tumour suppressor factor
US20050013803A1 (en) * 2000-07-07 2005-01-20 Benjamin Thomas L. Diagnosing and treating cancer cells using mutant viruses
US20030157481A1 (en) * 2001-12-10 2003-08-21 Benjamin Thomas L. Diagnosing and treating cancer cells using T-HR mutants and their targets
US20030093819A1 (en) 2000-11-03 2003-05-15 D'andrea Alan D. Methods and compositions for the diagnosis of cancer susceptibilities and defective DNA repair mechanisms and treatment thereof
US20030188326A1 (en) * 2000-11-03 2003-10-02 Dana Farber Cancer Institute Methods and compositions for the diagnosis of cancer susceptibilities and defective DNA repair mechanisms and treatment thereof
US6816789B2 (en) * 2001-04-19 2004-11-09 Varian, Inc. Method and system for analyzing chromatograms
AU2002323841B2 (en) * 2001-06-05 2008-05-22 Auckland Uniservices Limited Methods and compositions for assessment of pulmonary function and disorders
AU2002359398A1 (en) * 2001-11-16 2003-06-10 Exelixis, Inc. Nucleic acids and polypeptides of invertebrate brca2 and methods of use
CA2468197A1 (fr) * 2001-11-29 2003-06-05 Therakos, Inc. Methodes permettant de pretraiter un sujet au moyen d'une photopherese extracorporelle et/ou de cellules apoptotiques
CA2608142A1 (fr) * 2005-05-10 2006-11-16 Synergenz Bioscience Limited Procedes et compositions pour l'evaluation de la fonction et de troubles pulmonaires
CA2608161A1 (fr) * 2005-05-19 2006-11-23 Synergenz Bioscience Limited Procedes et compositions d'evaluation des fonctions et troubles pulmonaires
AU2006248200A1 (en) * 2005-05-19 2006-11-23 Synergenz Bioscience Limited Methods and compositions for assessment of pulmonary function and disorders
US7933722B2 (en) * 2005-05-20 2011-04-26 Synergenz Bioscience Limited Methods of analysis of polymorphisms and uses thereof
IL282783B2 (en) 2006-05-18 2023-09-01 Caris Mpi Inc A system and method for determining a personalized medical intervention for a disease stage
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
PL2134876T3 (pl) * 2006-06-22 2014-10-31 Pomorski Univ Medyczny Określanie predyspozycji do raka piersi poprzez identyfikację kombinacji genotypu specyficznych wariantów genów CYP1B1, BRCA2 oraz CHEK2
WO2008021288A2 (fr) * 2006-08-11 2008-02-21 Johns Hopkins University Séquences codantes consensus de cancers du sein et colorectaux humains
US7993835B1 (en) * 2007-05-11 2011-08-09 Myriad Genetics, Inc. BRCA2 mutations and use thereof
EP3075864A1 (fr) * 2008-10-14 2016-10-05 Caris MPI, Inc. Gène et protéine exprimées par des gènes cibles représentant des profils de biomarqueurs et ensembles de signature par type de tumeurs
CN107254538A (zh) * 2008-11-12 2017-10-17 卡里斯生命科学瑞士控股有限责任公司 使用外来体来确定表现型的方法和系统
US20130029926A1 (en) * 2009-11-05 2013-01-31 Myriad Genetics, Inc. Compositions and methods for determing cancer susceptibility
JP5808349B2 (ja) 2010-03-01 2015-11-10 カリス ライフ サイエンシズ スウィッツァーランド ホールディングスゲーエムベーハー セラノーシスのためのバイオマーカー
CA2795776A1 (fr) 2010-04-06 2011-10-13 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Biomarqueurs circulants pour une maladie
US20130018700A1 (en) * 2011-07-14 2013-01-17 International Business Machines Corporation Optimizing product portfolios under customer choice
US20140222512A1 (en) * 2013-02-01 2014-08-07 Goodsnitch, Inc. Receiving, tracking and analyzing business intelligence data
US20140343982A1 (en) * 2013-05-14 2014-11-20 Landmark Graphics Corporation Methods and systems related to workflow mentoring
CN106852176A (zh) * 2014-03-25 2017-06-13 凡弗3基因组有限公司 用于功能证实癌症突变的rna分析的系统和方法
US10133996B2 (en) * 2014-04-22 2018-11-20 International Business Machines Corporation Object lifecycle analysis tool
CN104962613B (zh) * 2015-06-02 2019-12-03 南京医科大学 一种用于乳腺癌辅助诊断的突变基因及其应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
CA1188246A (fr) 1981-08-31 1985-06-04 Jerry L. Gregory Appareil de fermentation en continue contenant un microorganisme immobilise
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4868105A (en) 1985-12-11 1989-09-19 Chiron Corporation Solution phase nucleic acid sandwich assay
IE61148B1 (en) 1988-03-10 1994-10-05 Ici Plc Method of detecting nucleotide sequences
US5773278A (en) † 1991-05-03 1998-06-30 Mount Sinai Medical Center Acid sphingomyelinase gene
IL103059A0 (en) 1991-09-30 1993-02-21 Boehringer Ingelheim Int Conjugates for introducing nucleic acid into higher eucaryotic cells
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
AU1214995A (en) * 1993-11-30 1995-06-19 California Pacific Medical Center Research Institute Cdna probe for breast cancer diagnosis and treatment
WO1995019369A1 (fr) * 1994-01-14 1995-07-20 Vanderbilt University Procede de detection et de traitement du cancer du sein
ATE259378T1 (de) * 1995-11-23 2004-02-15 Cancer Res Campaign Tech Materialien und methoden mit bezug zur identifizierung und sequenzierung des krebs- suszeptilitaetsgens brca2 und dessen anwendungen
GB2307477B (en) * 1995-11-23 1997-10-22 Cancer Res Campaign Tech Materials and methods relating to the identification and sequencing of the BRCA2 cancer susceptibility gene and uses thereof
US5879890A (en) † 1997-01-31 1999-03-09 The Johns Hopkins University APC mutation associated with familial colorectal cancer in Ashkenazi jews
CA2289109A1 (fr) † 1997-04-30 1998-11-05 Genzyme Limited Syndrome de type 1 consecutif a une deficience glucidique de la glycoproteine
WO1998055650A1 (fr) † 1997-06-04 1998-12-10 Rijksuniversiteit Te Leiden Trousse de controle diagnostique servant a determiner une predisposition au cancer du sein et des ovaires, materiaux et procedes servant a effectuer cette determination
US6376176B1 (en) † 1999-09-13 2002-04-23 Cedars-Sinai Medical Center Methods of using a major histocompatibility complex class III haplotype to diagnose Crohn's disease
BR0109192A (pt) † 2000-03-16 2003-05-27 Sucampo Ag Tratamento de hipertensão ocular e glaucoma.
EP1280814A4 (fr) † 2000-04-13 2003-05-14 Genaissance Pharmaceuticals Association d'haplotypes du recepteur adrenergique beta2 reagissant aux medicaments
EP1430081A2 (fr) † 2001-06-13 2004-06-23 Centre National De La Recherche Scientifique (Cnrs) Complexes moleculaires brca1/acc alpha, applications diagnostiques et therapeutiques

Also Published As

Publication number Publication date
NO982785D0 (no) 1998-06-17
ATE230759T1 (de) 2003-01-15
IL124620A0 (en) 1998-12-06
EP0785216B2 (fr) 2006-06-07
EP0785216B1 (fr) 2003-01-08
DE69625678T3 (de) 2006-11-09
CA2239733C (fr) 2001-04-03
NO982785L (no) 1998-08-17
WO1997022689A1 (fr) 1997-06-26
NZ326525A (en) 1999-11-29
US6033857A (en) 2000-03-07
AU1461597A (en) 1997-07-14
DE69625678D1 (de) 2003-02-13
EP0785216A1 (fr) 1997-07-23
JP3455228B2 (ja) 2003-10-14
DE69625678T2 (de) 2003-11-06
US6124104A (en) 2000-09-26

Similar Documents

Publication Publication Date Title
CA2239733A1 (fr) Gene de predisposition au cancer du sein lie au chromosome 13
EP1260520A3 (fr) Gène BRCA2 impliqué dans la susceptibilité au cancer du sein , du chromosome 13,
CA2196795A1 (fr) Procede pour diagnostiquer une predisposition au cancer du sein et des ovaires
CA2196797A1 (fr) Polymorphismes et mutations in vivo chez le gene de susceptibilite 17q associe au cancer du sein et des ovaires
MX9701074A (es) Gen de susceptibilidad al cancer de pecho y ovario enlazado con 17q.
WO2001085911A3 (fr) Gene de sensibilite au cancer de la prostate lie au chromosome 17p et paralogue et genes orthologues
WO1999053062A3 (fr) Genes sh3 associes au syndrome myeloproliferatif et a la leucemie, et utilisation de ces genes

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20161219